<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00654056</url>
  </required_header>
  <id_info>
    <org_study_id>UKO-M20070267</org_study_id>
    <nct_id>NCT00654056</nct_id>
  </id_info>
  <brief_title>Severe Insulin Resistance in Patients With Type 2 Diabetes</brief_title>
  <official_title>Severe Insulin Resistance in Patients With Type 2 Diabetes: Mechanisms Behind Insulin Resistance.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Aarhus University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Regionshospitalet Silkeborg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to investigate some of the mechanisms behind severe insulin
      resistance and to determine the dose response to insulin in patients with type 2 diabetes
      mellitus.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Overnutrition and obesity are pivotal to the metabolic syndrome and diabetes. The sedentary
      lifestyle and overly rich nutrition are predominant in Western societies and result in
      obesity, insulin resistance and type 2 diabetes mellitus. According to the WHO an escalating
      global epidemic of overweight and obesity is sweeping the globe and the prevalence of type 2
      diabetes mellitus rises in parallel at the same alarming rate. It is likely that inherited
      insulin resistance relates to subtle mutations in many metabolic genes. It is still unclear
      whether such abnormalities lead to different proteomic patterns in target tissues (muscle and
      fat) and how intracellular hormone signaling is affected. Some patients with type 2 diabetes
      mellitus have severe insulin resistance with insulin requirements of more than 100 units/day
      and are still not optimally controlled. Our aim of this study is to examine the mechanisms
      behind severe insulin resistance and to elucidate how intracellular hormone signaling is
      affected, especially in relation to proteomics. Moreover we wish to determine the dose
      response to insulin in patients with type 2 diabetes mellitus with severe insulin resistance
      in order to see if there is a measurable effect on blood glucose at high insulin doses.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Insulin sensitivity</measure>
    <time_frame>8 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in insulin signaling proteins?</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>L1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Actrapid infusion, 0.5 mU/kg/min.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>L2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Actrapid infusion 1.5 mU/kg/min</description>
  </arm_group>
  <arm_group>
    <arm_group_label>H1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Actrapid infusion 3.0 mU/kg/min</description>
  </arm_group>
  <arm_group>
    <arm_group_label>H2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Actrapid infusion 5.0 mU/kg/min</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Actrapid (human insulin)</intervention_name>
    <description>On day one: 0,5 IU/kg/min for 3 hours, 1,5 IU/kg/min for 3 hours, on day two: 3,0 IU/kg/min for 3 hours, 5,0 IU/kg/min for 3 hours</description>
    <arm_group_label>L1</arm_group_label>
    <arm_group_label>L2</arm_group_label>
    <arm_group_label>H1</arm_group_label>
    <arm_group_label>H2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 25-75 years old

          -  BMI between 25 and 42

        Exclusion Criteria:

          -  Severe diseases
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Niels Moeller, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department M (Endocrinology and diabetes), Aarhus University Hospital, Nørrebrogade 44, 8000 Århus C, Denmark</affiliation>
  </overall_official>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 25, 2008</study_first_submitted>
  <study_first_submitted_qc>April 2, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 7, 2008</study_first_posted>
  <last_update_submitted>March 8, 2013</last_update_submitted>
  <last_update_submitted_qc>March 8, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 11, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Type 2 diabetes</keyword>
  <keyword>Severe insulin resistance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

